We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts (MDRX) Acknowledged by LPP's CDIS Framework
Read MoreHide Full Article
Renowned information technology and service provider to healthcare organizations, Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) recently announced that it has been accepted and acknowledged by the NHS London Procurement Partnership (LPP) in its Clinical and Digital Information Systems (CDIS) Framework.
Notably, LPP is a membership organization, founded and funded by the NHS organizations. The NHS spends almost £18 billion across England and Wales for improvement of healthcare by supporting collaboration among acute, mental health, community and primary care organizations. The CDIS platform under LPP provides a unified solution for efficient management of key clinical and administrative data to organizations. Organizations that are on the CDIS platform comply with the National Information Board’s Personalised Health and Care 2020 framework as well. CDIS gives access to a suite of software applications to the companies registered on the platform.
Notably, Allscripts has been accepted onto the CDIS framework for its Sunrise Electronic Patient Record platform, CareInMotion and 2bPrecise population health IT solutions.
A glimpse of the price trend of the company reveals that the stock has had an impressive run on the bourse year to date. Allscripts added 16.9%, comparing favorably with the Zacks classified Medical Info Systems sub-industry’s gain of 14.1%. Also, the current level compares favorably with the S&P 500’s return of 6.6% over the same time frame.
Despite the bullish price trend, estimate revision for the stock has been dismal. The full year has seen seven analysts move south over the last one month, with one movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year dropped 6% to 47 cents over the same time frame. Notably, the stock has Zacks Rank #3 (Hold).
Allscripts has been gaining prominence in the markets with its broad array of products that include Sunrise, CareInMotion and 2bPrecise. Per management, the company would be able to provide its clients with superior quality of healthcare and fortify its position in the niche markets with the latest development.
This also closely follows the recent launch of Clinical Pathways program for the treatment of cancer. The platform was launched in collaboration with Cancer Treatment Centers of America (CTCA), a national network of five hospitals that serve adult cancer patients and NantHealth, a member of the NantWorks ecosystem of companies (read more: Allscripts Launches Clinical Pathways for Cancer Treatment).
Bottom Line
Allscripts’ management is focused on various restructuring initiatives such as streamlining operational efficiency, increasing R&D and catering to client needs. We believe favorable demographic trends, reinforced by a supportive regulatory environment, are expected to sustain growth in demand of its services.
Higher client demand for the company’s population health management solutions by healthcare systems, hospitals and ambulatory markets should also drive growth over the long haul.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% in the last quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Allscripts (MDRX) Acknowledged by LPP's CDIS Framework
Renowned information technology and service provider to healthcare organizations, Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) recently announced that it has been accepted and acknowledged by the NHS London Procurement Partnership (LPP) in its Clinical and Digital Information Systems (CDIS) Framework.
Notably, LPP is a membership organization, founded and funded by the NHS organizations. The NHS spends almost £18 billion across England and Wales for improvement of healthcare by supporting collaboration among acute, mental health, community and primary care organizations. The CDIS platform under LPP provides a unified solution for efficient management of key clinical and administrative data to organizations. Organizations that are on the CDIS platform comply with the National Information Board’s Personalised Health and Care 2020 framework as well. CDIS gives access to a suite of software applications to the companies registered on the platform.
Notably, Allscripts has been accepted onto the CDIS framework for its Sunrise Electronic Patient Record platform, CareInMotion and 2bPrecise population health IT solutions.
A glimpse of the price trend of the company reveals that the stock has had an impressive run on the bourse year to date. Allscripts added 16.9%, comparing favorably with the Zacks classified Medical Info Systems sub-industry’s gain of 14.1%. Also, the current level compares favorably with the S&P 500’s return of 6.6% over the same time frame.
Despite the bullish price trend, estimate revision for the stock has been dismal. The full year has seen seven analysts move south over the last one month, with one movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year dropped 6% to 47 cents over the same time frame. Notably, the stock has Zacks Rank #3 (Hold).
Allscripts has been gaining prominence in the markets with its broad array of products that include Sunrise, CareInMotion and 2bPrecise. Per management, the company would be able to provide its clients with superior quality of healthcare and fortify its position in the niche markets with the latest development.
This also closely follows the recent launch of Clinical Pathways program for the treatment of cancer. The platform was launched in collaboration with Cancer Treatment Centers of America (CTCA), a national network of five hospitals that serve adult cancer patients and NantHealth, a member of the NantWorks ecosystem of companies (read more: Allscripts Launches Clinical Pathways for Cancer Treatment).
Bottom Line
Allscripts’ management is focused on various restructuring initiatives such as streamlining operational efficiency, increasing R&D and catering to client needs. We believe favorable demographic trends, reinforced by a supportive regulatory environment, are expected to sustain growth in demand of its services.
Allscripts Healthcare Solutions, Inc. Price
Allscripts Healthcare Solutions, Inc. Price | Allscripts Healthcare Solutions, Inc. Quote
Higher client demand for the company’s population health management solutions by healthcare systems, hospitals and ambulatory markets should also drive growth over the long haul.
Stocks to Consider
Better-ranked stocks in the broader medical sector include IDEXX Laboratories, Inc. (IDXX - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corp. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks (Strong Buy) here.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% in the last quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>